Overview: BCL6 Immunohistochemistry TestIntroduction: The BCL6 Immunohistochemistry Test detects BCL-6 protein to diagnose lymphomas, causing lymph node swelling or fatigue. Following 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected lymphomas, particularly diffuse large B-cell lymphoma.
Other Names: BCL-6 IHC Assay, Lymphoma BCL-6 Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: BCL-6 testing emerged in the 1990s with lymphoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision for lymphoid malignancies.
Purpose: Detects BCL-6 protein to diagnose lymphomas, guides treatment, and evaluates patients with lymph node swelling or fatigue.
Test Parameters: 1. BCL-6 Protein
Pretest Condition: No fasting required. Collect tissue via biopsy. Report history of lymph node swelling, fatigue, or lymphoma symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lymph node swelling, fatigue, night sweats, or family history of lymphomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, lymphoma implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect BCL-6 protein in lymphoid tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for lymphoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive BCL-6 staining suggests diffuse large B-cell lymphoma or follicular lymphoma, guiding chemotherapy or immunotherapy. Negative staining may require further lymphoma marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: BCL-2 IHC, CD20 IHC, or FISH for BCL-6 rearrangement to confirm lymphoma diagnosis.
Test Limitations: Not specific to one lymphoma type; other conditions may express BCL-6. Clinical correlation is needed.
References: WHO Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
